Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells

Simple item page
dc.contributor.authorSezer, Gülayen_US
dc.contributor.authorCaner, Arma?anen_US
dc.contributor.authorÖnal, Müge Gülcihanen_US
dc.contributor.authorCumao?lu, Ahmeten_US
dc.date.accessioned2023-08-19T04:52:29Z
dc.date.available2023-08-19T04:52:29Z
dc.date.issued2022-07
dc.description.abstractBackground & objectives: Several studies have provided evidence that opioids may play a role in cancer recurrence and metastasis. Multiple research data indicate that morphine can act as a proliferative or suppressive agent on tumour cells depending on the applied concentration. Therefore, this study was aimed to investigate whether the presence of clinically relevant concentrations of morphine has any effect on the efficacy of paclitaxel, a widely used chemotherapeutic drug, on the viability and apoptosis of human triple-negative breast cancer cell line. Methods: MDA.MB.231 cells were treated with paclitaxel in the presence or absence of morphine and examined for cell proliferation by the MTT assay. In addition, the effect of morphine on paclitaxel- induced apoptosis was investigated by flow cytometric assay and by the ratio of Bax/Bcl-2 mRNA expression levels with quantitative real-time (qRT)-PCR. Results: Morphine significantly increased the proliferation of breast cancer cells at low concentrations (0.1-2.5 ?M) but higher concentrations showed cytotoxic effect. Pre-treatment with 0.1 or 1 ?M of morphine decreased the paclitaxel-induced cytotoxicity, the proportion of apoptotic cell, and the ratio of Bax/Bcl-2 mRNA expressions. Interpretation & conclusions: Our data suggest that morphine promotes breast cancer cell viability at clinically relevant plasma concentrations and reduces the apoptotic effect of paclitaxel. This interaction may be very important in clinical settings; however, more studies are needed to explore the plausible mechanisms of interaction and to correlate such findings through in vivo animal studies as well as clinically.en_US
dc.identifier.affiliationsDepartments ofen_US
dc.identifier.affiliationsPharmacologyen_US
dc.identifier.affiliationsBiophysicsen_US
dc.identifier.affiliationsMedical Biology, School of Medicine, University of Erciyesen_US
dc.identifier.affiliationsDepartment of Biochemistry, School of Pharmacy &en_US
dc.identifier.affiliationsGenkök Genome and Stem Cell Center, University of Erciyes, Kayseri, Turkeyen_US
dc.identifier.citationSezer Gülay, Caner Arma?an, Önal Müge Gülcihan, Cumao?lu Ahmet. Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells. Indian Journal of Medical Research. 2022 Jul; 156(1): 70-76en_US
dc.identifier.issn0971-5916
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223690
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume156en_US
dc.source.urihttps://doi.org/10.4103/ijmr.IJMR_2443_19en_US
dc.subjectApoptosisen_US
dc.subjectin vitroen_US
dc.subjectMDA.MB.231en_US
dc.subjectmorphineen_US
dc.subjectopioiden_US
dc.subjectpaclitaxelen_US
dc.subjecttriple-negative breast canceren_US
dc.titleMorphine counteracts the effects of paclitaxel in triple-negative breast cancer cellsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMR2022v156n1p70.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research